 ATLANTA, Sept. 23, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase or Company, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced that the Company has been awarded a 385,388 research grant from the U.S. National Institute of Neurological Disease and Stroke NINDS, an Institute of the National Institutes of Health NIH, to evaluate the therapeutic potential of IkT-148009, the Companys lead c-Abl inhibitor, in a novel preclinical model for Multiple System Atrophy MSA. 